Oxygenta Pharmaceutical has acquired a land parcel measuring 36,421 square metres in Sangareddy District, Telangana, for a total consideration of ₹6.75 crore. The acquisition aims to support the company's long-term strategic requirements and enhance operational capabilities.

The final allotment letter was issued by the Telangana Industrial Infrastructure Corporation Limited (TGIIC) on October 1, 2026. The transaction involves Plot No. UDL-1 located at UDL-Aroor, Sangareddy District. This purchase exceeds the materiality threshold prescribed under Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, necessitating disclosure to stock exchanges.

Acquisition details

The company disclosed the specifics of the immovable property acquisition under Regulation 30 of the SEBI LODR Regulations. The land is intended to facilitate future expansion and establish additional infrastructure.

Strategic rationale

The management stated that the acquisition is undertaken to support business operations and facilitate future expansion. The new infrastructure is expected to meet the company's long-term strategic requirements and provide adequate capacity for anticipated business growth. The move aligns with the company's objective to enhance operational capabilities through physical asset expansion.

Oxygenta Pharmaceutical concluded its 33rd Annual General Meeting on August 21, 2026, with shareholders approving all seven resolutions placed before them. The meeting was held via video conferencing.

A total of 4,472,167 votes were polled out of 36,983,500 shares held by shareholders on the record date of August 14, 2026. This represents a turnout of approximately 12.09% of outstanding shares. The promoter group held 20,909,870 shares but did not cast any votes during the remote e-voting or the meeting.

Voting Results Overview

The voting process was scrutinized by M/s. Aakanksha Dubey & Co. Participation included 75 members via video conferencing (73 public, 2 promoters) and remote e-voting. Notably, public non-institutional shareholders accounted for all votes cast, with a participation rate of 27.84% among that category.

Key Approvals

Shareholders approved two ordinary resolutions concerning material related-party transactions with the holding company, Virupaksha Organics Limited. These covered sales and purchase agreements, as well as loan and guarantee facilities. While these resolutions passed comfortably, they received slightly higher dissent than other agenda items, with 109 votes cast against the loan and guarantee resolution compared to just one vote against most other items.

The Board also ratified the remuneration for the cost auditor for the financial year 2026-27. All directors and key managerial personnel, including CFO Mr. Prasad Reddy Battinapatla and Company Secretary Ms. Kumkum Bajaj, attended the meeting to address member queries regarding financials and future outlook.